Cargando…

Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD

Our understanding of the pathogenesis of Alzheimer disease (AD) has been greatly influenced by investigation of rare families with autosomal dominant mutations that cause early onset AD. Mutations in the genes coding for amyloid precursor protein (APP), presenilin 1 (PSEN-1), and presenilin 2 (PSEN-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schindler, Suzanne Elizabeth, Fagan, Anne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483518/ https://www.ncbi.nlm.nih.gov/pubmed/26175713 http://dx.doi.org/10.3389/fneur.2015.00142

Ejemplares similares

Dynamic Causal Modeling of Preclinical Autosomal-Dominant Alzheimer’s Disease
por: Penny, Will, et al.
Publicado: (2018)

CSF sTREM2: marking the tipping point between preclinical AD and dementia?
por: Schindler, Suzanne E, et al.
Publicado: (2016)

Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2022)

CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
por: van der Ende, Emma L, et al.
Publicado: (2023)

GPS driving: a digital biomarker for preclinical Alzheimer disease
por: Bayat, Sayeh, et al.
Publicado: (2021)

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
por: Strain, Jeremy F., et al.
Publicado: (2022)

Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease
por: Muenchhoff, Julia, et al.
Publicado: (2016)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
por: Müller, Stephan, et al.
Publicado: (2017)

Diurnal oscillation of CSF Aβ and other AD biomarkers
por: Lucey, Brendan P., et al.
Publicado: (2017)

Discovery and validation of autosomal dominant Alzheimer’s disease mutations
por: Hsu, Simon, et al.
Publicado: (2018)

CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
por: Dong, Ruocheng, et al.
Publicado: (2023)

Neural Networks in Autosomal Dominant Alzheimer’s Disease: Insights From Functional Magnetic Resonance Imaging Studies
por: Qiu, Qiongqiong
Publicado: (2022)

Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers
por: Leitão, Maria João, et al.
Publicado: (2015)

CSF p-tau231: A biomarker for early preclinical Alzheimer?
por: Suárez-Calvet, Marc
Publicado: (2022)

Autosomal Dominant Centronuclear Myopathy with Unique Clinical Presentations
por: Lee, Jee-Young, et al.
Publicado: (2007)

Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer’s Disease
por: Lopez-Font, Inmaculada, et al.
Publicado: (2015)

Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease
por: Norton, Daniel J., et al.
Publicado: (2020)

Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer’s disease
por: Guzmán-Vélez, Edmarie, et al.
Publicado: (2022)

microRNA-Based Biomarkers in Alzheimer’s Disease (AD)
por: Zhao, Yuhai, et al.
Publicado: (2020)

Should persons with autosomal dominant AD be included in clinical trials?
por: Grill, Joshua D, et al.
Publicado: (2011)

Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer’s Disease: The Paradigmatic Example of CSF
por: Canevelli, Marco, et al.
Publicado: (2019)

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer disease: a longitudinal study
por: Gordon, Brian A., et al.
Publicado: (2018)

Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
por: Younes, Laurent, et al.
Publicado: (2019)

Relationships between big‐five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2020)

First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease: the Dominantly Inherited Alzheimer’s Network Study
por: O'Connor, Antoinette, et al.
Publicado: (2023)

CSF1R Related Leukoencephalopathy - Rare Childhood Presentation of An Autosomal Dominant Microgliopathy!
por: Sriram, Neeharika, et al.
Publicado: (2022)

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease
por: Araque Caballero, Miguel Ángel, et al.
Publicado: (2018)

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018)

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
por: Johnson, Erik C. B., et al.
Publicado: (2023)

Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia
por: Oudart, Jean-Baptiste, et al.
Publicado: (2020)

Ophthalmic Manifestations and Genetics of the Polyglutamine Autosomal Dominant Spinocerebellar Ataxias: A Review
por: Park, Jun Young, et al.
Publicado: (2020)

Myriocin Effect on Tvrm4 Retina, an Autosomal Dominant Pattern of Retinitis Pigmentosa
por: Piano, Ilaria, et al.
Publicado: (2020)

Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer’s disease
por: Levitis, Elizabeth, et al.
Publicado: (2022)

Harmonization of CSF and imaging biomarkers for Alzheimer’s disease biomarkers: need and practical applications for genetics studies and preclinical classification
por: Timsina, Jigyasha, et al.
Publicado: (2023)

The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease
por: Vila-Castelar, Clara, et al.
Publicado: (2020)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Comparison of plasma and CSF biomarkers in predicting cognitive decline
por: Aschenbrenner, Andrew J., et al.
Publicado: (2022)

Should persons with autosomal dominant AD be included in clinical trials? Authors' response
por: Szigeti, Kinga, et al.
Publicado: (2011)

Falls: a marker of preclinical Alzheimer disease: a cohort study protocol
por: Bollinger, Rebecca M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7asa2k9iljk9j91k78daajftml